Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.03
ACOR's Cash to Debt is ranked lower than
79% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. ACOR: 1.03 )
Ranked among companies with meaningful Cash to Debt only.
ACOR' s 10-Year Cash to Debt Range
Min: 1.03  Med: 31.14 Max: N/A
Current: 1.03
Equity to Asset 0.50
ACOR's Equity to Asset is ranked lower than
69% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ACOR: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
ACOR' s 10-Year Equity to Asset Range
Min: -3.98  Med: 0.51 Max: 0.75
Current: 0.5
-3.98
0.75
Interest Coverage 3.92
ACOR's Interest Coverage is ranked lower than
95% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACOR: 3.92 )
Ranked among companies with meaningful Interest Coverage only.
ACOR' s 10-Year Interest Coverage Range
Min: 3.92  Med: 11.72 Max: 13.99
Current: 3.92
3.92
13.99
F-Score: 6
Z-Score: 2.10
M-Score: -2.77
WACC vs ROIC
8.68%
6.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 7.54
ACOR's Operating margin (%) is ranked higher than
77% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. ACOR: 7.54 )
Ranked among companies with meaningful Operating margin (%) only.
ACOR' s 10-Year Operating margin (%) Range
Min: -9345.93  Med: -92.85 Max: 12
Current: 7.54
-9345.93
12
Net-margin (%) 3.30
ACOR's Net-margin (%) is ranked higher than
71% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. ACOR: 3.30 )
Ranked among companies with meaningful Net-margin (%) only.
ACOR' s 10-Year Net-margin (%) Range
Min: -9340.5  Med: -92.00 Max: 50.67
Current: 3.3
-9340.5
50.67
ROE (%) 2.71
ACOR's ROE (%) is ranked higher than
76% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. ACOR: 2.71 )
Ranked among companies with meaningful ROE (%) only.
ACOR' s 10-Year ROE (%) Range
Min: -92.5  Med: -2.28 Max: 52.43
Current: 2.71
-92.5
52.43
ROA (%) 1.47
ACOR's ROA (%) is ranked higher than
77% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. ACOR: 1.47 )
Ranked among companies with meaningful ROA (%) only.
ACOR' s 10-Year ROA (%) Range
Min: -109.5  Med: -27.93 Max: 32.8
Current: 1.47
-109.5
32.8
ROC (Joel Greenblatt) (%) 112.94
ACOR's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. ACOR: 112.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACOR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4354.61  Med: -1601.84 Max: 1008.02
Current: 112.94
-4354.61
1008.02
Revenue Growth (3Y)(%) 9.00
ACOR's Revenue Growth (3Y)(%) is ranked higher than
63% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ACOR: 9.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACOR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.8  Med: 9.00 Max: 73.6
Current: 9
-61.8
73.6
EBITDA Growth (3Y)(%) 2.60
ACOR's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. ACOR: 2.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACOR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -80.8  Med: -67.75 Max: 20.5
Current: 2.6
-80.8
20.5
EPS Growth (3Y)(%) -17.90
ACOR's EPS Growth (3Y)(%) is ranked lower than
64% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. ACOR: -17.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACOR' s 10-Year EPS Growth (3Y)(%) Range
Min: -84  Med: -57.40 Max: -12.4
Current: -17.9
-84
-12.4
» ACOR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ACOR Guru Trades in Q3 2014

Joel Greenblatt 150,609 sh (+193.80%)
Jim Simons 97,900 sh (+135.90%)
Steven Cohen Sold Out
» More
Q4 2014

ACOR Guru Trades in Q4 2014

Steven Cohen 247,841 sh (New)
Joel Greenblatt 161,650 sh (+7.33%)
Jim Simons 54,100 sh (-44.74%)
» More
Q1 2015

ACOR Guru Trades in Q1 2015

Paul Tudor Jones 14,200 sh (New)
John Hussman 210,000 sh (New)
Jim Simons 319,000 sh (+489.65%)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
» More
Q2 2015

ACOR Guru Trades in Q2 2015

John Hussman 136,000 sh (-35.24%)
» More
» Details

Insider Trades

Latest Guru Trades with ACOR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 103.08
ACOR's P/E(ttm) is ranked lower than
78% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. ACOR: 103.08 )
Ranked among companies with meaningful P/E(ttm) only.
ACOR' s 10-Year P/E(ttm) Range
Min: 6.35  Med: 43.73 Max: 161.37
Current: 103.08
6.35
161.37
Forward P/E 26.95
ACOR's Forward P/E is ranked lower than
56% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. ACOR: 26.95 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 102.20
ACOR's PE(NRI) is ranked lower than
79% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. ACOR: 102.20 )
Ranked among companies with meaningful PE(NRI) only.
ACOR' s 10-Year PE(NRI) Range
Min: 6.35  Med: 43.33 Max: 157.52
Current: 102.2
6.35
157.52
P/B 2.62
ACOR's P/B is ranked higher than
73% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ACOR: 2.62 )
Ranked among companies with meaningful P/B only.
ACOR' s 10-Year P/B Range
Min: 2.32  Med: 4.81 Max: 44.88
Current: 2.62
2.32
44.88
P/S 3.47
ACOR's P/S is ranked higher than
80% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. ACOR: 3.47 )
Ranked among companies with meaningful P/S only.
ACOR' s 10-Year P/S Range
Min: 0.12  Med: 4.52 Max: 24.53
Current: 3.47
0.12
24.53
PFCF 26.83
ACOR's PFCF is ranked higher than
68% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 45.01 vs. ACOR: 26.83 )
Ranked among companies with meaningful PFCF only.
ACOR' s 10-Year PFCF Range
Min: 10.97  Med: 27.89 Max: 130.85
Current: 26.83
10.97
130.85
POCF 23.49
ACOR's POCF is ranked higher than
68% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. ACOR: 23.49 )
Ranked among companies with meaningful POCF only.
ACOR' s 10-Year POCF Range
Min: 9.61  Med: 24.73 Max: 66.66
Current: 23.49
9.61
66.66
EV-to-EBIT 44.04
ACOR's EV-to-EBIT is ranked lower than
58% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. ACOR: 44.04 )
Ranked among companies with meaningful EV-to-EBIT only.
ACOR' s 10-Year EV-to-EBIT Range
Min: -99.3  Med: -2.00 Max: 93.5
Current: 44.04
-99.3
93.5
Shiller P/E 63.13
ACOR's Shiller P/E is ranked lower than
58% of the 109 Companies
in the Global Biotechnology industry.

( Industry Median: 49.43 vs. ACOR: 63.13 )
Ranked among companies with meaningful Shiller P/E only.
ACOR' s 10-Year Shiller P/E Range
Min: 55.13  Med: 95.63 Max: 479.88
Current: 63.13
55.13
479.88
Current Ratio 3.47
ACOR's Current Ratio is ranked lower than
57% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. ACOR: 3.47 )
Ranked among companies with meaningful Current Ratio only.
ACOR' s 10-Year Current Ratio Range
Min: 0.59  Med: 3.70 Max: 8.36
Current: 3.47
0.59
8.36
Quick Ratio 3.09
ACOR's Quick Ratio is ranked lower than
58% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. ACOR: 3.09 )
Ranked among companies with meaningful Quick Ratio only.
ACOR' s 10-Year Quick Ratio Range
Min: 0.42  Med: 3.39 Max: 8.09
Current: 3.09
0.42
8.09
Days Inventory 141.96
ACOR's Days Inventory is ranked lower than
59% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. ACOR: 141.96 )
Ranked among companies with meaningful Days Inventory only.
ACOR' s 10-Year Days Inventory Range
Min: 14.56  Med: 215.14 Max: 332.51
Current: 141.96
14.56
332.51
Days Sales Outstanding 26.50
ACOR's Days Sales Outstanding is ranked higher than
80% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. ACOR: 26.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACOR' s 10-Year Days Sales Outstanding Range
Min: 28.51  Med: 38.87 Max: 1465.33
Current: 26.5
28.51
1465.33

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.49
ACOR's Price/Projected FCF is ranked higher than
86% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ACOR: 1.49 )
Ranked among companies with meaningful Price/Projected FCF only.
ACOR' s 10-Year Price/Projected FCF Range
Min: 1.44  Med: 2.99 Max: 22.28
Current: 1.49
1.44
22.28
Price/Median PS Value 0.77
ACOR's Price/Median PS Value is ranked higher than
76% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. ACOR: 0.77 )
Ranked among companies with meaningful Price/Median PS Value only.
ACOR' s 10-Year Price/Median PS Value Range
Min: 0.04  Med: 1.02 Max: 4.88
Current: 0.77
0.04
4.88
Earnings Yield (Greenblatt) (%) 2.30
ACOR's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ACOR: 2.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACOR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.1  Med: 2.90 Max: 7.7
Current: 2.3
1.1
7.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CDG.Germany,
Acorda Therapeutics Inc was incorporated on March 17, 1995 as a Delaware corporation. It is a biopharmaceutical company, engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The first product for which it completed clinical development, Ampyra (dalfampridine) Extended Release Tablets, 10mg was approved by the U.S. Food and Drug Administration, or FDA, in January 2010 as a treatment to improve walking in patients with MS. Ampyra is marketed as Fampyra outside the U.S. by Biogen Idec International GmbH, or Biogen Idec. The Company also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug approved by the FDA for the management of spasticity. The Company is developing a pipeline of novel neurological therapies. It is studying dalfampridine to improve a range of functional impairments, in addition to walking disability, caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, it is developing its clinical stage compound AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and SCI. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in SCI. It also has trademark registrations for "Fampyra" and "Kampyra" and pending trademark applications therefor, in numerous foreign jurisdictions. It also owns the rights to the registered marks "Zanaflex" and "Zanaflex Capsules" and "Qutenza" in the U.S. In addition, its trademark portfolio includes several trademark registrations and pending trademark applications for potential product names and for disease awareness activities. The Company is subject to periodic unannounced inspections by the FDA and other regulatory bodies related to the other regulatory requirements that apply to marketed drugs manufactured or distributed by the Company.
» More Articles for ACOR

Headlines

Articles On GuruFocus.com
Fv 58 MSN 10 Apr 19 2013 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Acorda Therapeutics Inc. Reports Operating Results (10-K) Mar 01 2011 
Steve Cohen Buys ACOR, DPZ, GXDX, NDN, and OREX Feb 07 2011 
Acorda Therapeutics Inc. (ACOR) President and CEO Ron Cohen sells 15,000 Shares Dec 03 2010 
Acorda Therapeutics Inc. (ACOR) CFO David Lawrence sells 10,905 Shares Dec 03 2010 
Acorda Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Acorda Therapeutics Inc. (ACOR) President and CEO Ron Cohen sells 55,000 Shares Aug 09 2010 
Acorda Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Acorda Therapeutics Inc. (ACOR) CFO David Lawrence sells 12,000 Shares Mar 12 2010 

More From Other Websites
Acorda 2Q Earnings & Revenues Top, Ampyra in Focus - Analyst Blog Jul 31 2015
Edited Transcript of ACOR earnings conference call or presentation 30-Jul-15 12:30pm GMT Jul 30 2015
ACORDA THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of... Jul 30 2015
6:47 am Acorda Therapeutics beats by $0.14, beats on revs Jul 30 2015
Acorda beats Street 2Q forecasts Jul 30 2015
Acorda beats Street 2Q forecasts Jul 30 2015
Acorda Provides Financial and Pipeline Update for 2015 Second Quarter Jul 30 2015
Secret IPO Filings Feed Deal Frenzy Jul 28 2015
Acorda Therapeutics to Host Conference Call to Discuss Second Quarter Results on July 30, 2015 Jul 23 2015
Acorda Therapeutics to Host Conference Call to Discuss Second Quarter Results on July 30, 2015 Jul 23 2015
New 'trolls' are crushing innovation in biopharma Jul 22 2015
ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 22 2015
Acorda Awarded Grant to Study ARCUS® Technology in Respiratory Distress Syndrome Jul 22 2015
Acorda Awarded Grant to Study ARCUS® Technology in Respiratory Distress Syndrome Jul 22 2015
Bass Goes Fishing: Trouble Ahead For Pharma, Or For Hedge-Fund Trolls? Jul 15 2015
Are Patent Challenges Paying Off For Kyle Bass? Jul 06 2015
AMAG Down on Cord Blood Registry Deal for $700 Million - Analyst Blog Jun 30 2015
Acorda Data on Inhaled Levodopa Therapy CVT-301 Recognized in Blue Ribbon Highlights Session at... Jun 24 2015
Acorda Data on Inhaled Levodopa Therapy CVT-301 Recognized in Blue Ribbon Highlights Session at... Jun 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK